A randomized, single-blind, parallel group, multiple oral dose study to evaluate the effect of a light meal on the pharmacokinetics and pharmacodynamics of aliskiren using market 300 mg tablet formulation in subjects with mild to moderate hypertension.
Phase of Trial: Phase IV
Latest Information Update: 24 Aug 2016
At a glance
- Drugs Aliskiren (Primary)
- Indications Essential hypertension
- Focus Pharmacodynamics; Pharmacokinetics
- Sponsors Novartis Pharmaceuticals
- 10 Jun 2017 Biomarkers information updated
- 05 Feb 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 08 Jul 2009 Planned number of patients changed from 122 to 150 as reported by ClinicalTrials.gov.